Evidence map›Paper›PMID 40756825›Full record

ArticleJournal of the Royal Society of New Zealand2025

Implementing genomic medicine in New Zealand.

Richard I King

Abstract read
In one paragraph

Article in Journal of the Royal Society of New Zealand, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Richard I KingDepartment of Pathology, University of Otago, Christchurch, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genomic sequencing is a transformative technology, and its integration and implementation in the practice of medicine requires systemwide change. Genomic technology is already influencing many areas of medicine: rare disease, reproductive health, cancer, pharmacogenetics and infectious disease. Ensuring genomic tests are available and are adopted in an effective and efficient way requires forethought and simultaneous change across multiple areas of health. Beyond the technical requirements of sequencing and bioinformatics capacity, planning will need to address data integration and interpretation, workforce capacity and capability, public acceptability, government engagement and ethical and legislative issues. To ensure all these considerations are managed, many states or nations have developed policy frameworks or strategies. Implementation science enables us to understand the factors that support adoption of new technologies. The lessons learnt from other jurisdictions who have implemented genomic medicine programmes clearly support the need for a coordinated whole of systems approach. New Zealand should heed these lessons. New Zealand needs a genomic medicine strategy.

Indexed as

Genomic medicinegenomicsgenomics strategyimplementationprecision health

Identifiers

PMID40756825
PMCPMC12315147

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.